Haisco Pharmaceutical Group Co., Ltd.

This study is testing whether an investigational drug called HSK47388 can help control symptoms and reduce inflammation in adults with moderate to severe ulcerative colitis. Researchers will compare HSK47388 against a placebo in about 150 participants whose current treatments are…

This study is testing whether an experimental tablet called HSK39297 can help control IgA nephropathy, a kidney disease. About 370 adults with confirmed IgA nephropathy will take either the real tablet or a placebo for up to two years. Researchers will measure how well the drug r…

This is an early-stage study to find a safe dose and see how well a new oral tablet called HSK47977 works for adults with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. Researchers will test different dose levels in about 110 participants to chec…

This study is testing whether a new daily pill called HSK39297 can help control lupus nephritis, a serious kidney disease caused by lupus. About 105 adults with active kidney inflammation will take either the real pill or a placebo, along with standard care, to see if it reduces …

This is an early-stage study to find a safe dose and learn how the body processes a new oral drug called HSK42360. It is for children and teenagers (ages 6-17) whose aggressive brain tumors have a specific BRAF V600 mutation and have come back after standard treatments. The main …

This study is testing a new pain medication called HSK21542 for people who have just had hip replacement surgery. It will compare the new injection to standard morphine and a placebo (inactive substance) to see which works better at relieving pain and causes fewer side effects li…

This early-stage study aims to understand how a potential new drug for a rare blood disease (Paroxysmal Nocturnal Hemoglobinuria or PNH) is processed by the body in people with mild to moderate liver problems. It will compare the drug's levels and safety in 24 people who have liv…